Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Generic Competitors A Looming Threat For Acorda Therapeutics Inc (ACOR)

In order to ensure an extension of Ampyra’s protection to 2026, Acorda Therapeutics Inc (NASDAQ:ACOR) must fight off competition from competitors such as Roxane, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), and Mylan NV (NASDAQ:MYL) as well as ensure it keeps its patents. This is according to Michael Yee, an RBC analyst.

Ten companies have been sued by Acorda to stop them from filing generic versions of its MS drug, Ampyra and the decision over whether Acorda will get to retain any or all of the drug’s patents is still being awaited. In the first case, the decision could be made any day now while in the second case the decision might not be made until mid-March.

“If they lose either court case or inter partes review case, then Ampyra could see generics enter in 2018 since the court case defines if generics are infringing and the IPR defines if they can even keep the patent,” a research report written by Michael Yee read.

Fall In EPS

On Tuesday, Acorda Therapeutics Inc (NASDAQ:ACOR)’s financial results for the fourth quarter of 2016 showed sales figures of $140.6 million. This was a 7.4 percent rise year-on-year and beat consensus estimates of $138.7 million. Earnings per share, however, fell by 82 percent when they came in at 5 cents, while estimates had expected 10 cents.

In the earnings call, analysts focused on the ongoing litigation concerning Ampyra. Some analysts even wondered whether Ampyra should be included in their models for 2017.

Ongoing Litigation Casts A Dark Shadow

Acorda’s sales projections for 2017 range between $535 million and $545 million. If Acorda loses either of the cases in the ongoing litigation, it will adjust the projections accordingly. Most analysts say the outcome of the litigation is hard to predict.

Despite the dark shadows looming over the biotech firm, Acorda has a drug for treating Parkinson’s lined up, CVT-301, which is expected to get approval from the U.S. Food and Drug Administration sometime in 2018. Results from the phase III trial of the drug, which were released last week, were largely positive.

On Wednesday, shares of Acorda Therapeutics Inc (NASDAQ:ACOR) shot up by 6.5 percent to close the day at $25.40.

Follow Acorda Therapeutics Inc (NASDAQ:ACOR)
Trade (NASDAQ:ACOR) Now!

Note: This article is written by Andy Parker and was originally published at Market Exclusive.

Loading Comments...